Novartis has agreed to purchase a US and Australian-based privately held development stage company Spinifex Pharmaceuticals for an undisclosed amount.

According to Business Spectator, the deal is valued at more than $200m and will also include undisclosed ‘significant’ milestone payments.

Spinifex specialises in therapies for chronic pain and is currently focused on developing EMA401, a novel angiotensin II Type 2 receptor (AT2R) antagonist to treat neuropathic pain.

"EMA401 could provide a novel, differentiated treatment approach to provide relief for patients and healthcare providers worldwide."

EMA401 is a differentiated treatment for neuropathic pain acting outside the blood-brain barrier, which is expected to avoid significant central nervous system side-effects.

Novartis Pharmaceuticals head David Epstein said: "Neuropathic pain is a chronic and debilitating condition with high unmet need. EMA401 could provide a novel, differentiated treatment approach to provide relief for patients and healthcare providers worldwide."

In a Phase II clinical trial, Spinifex’s EMA401 was assessed for its efficacy in post-herpetic neuralgia, a painful condition that develops in some people following herpes zoster (shingles).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial also observed that EMA401 showed no central nervous system side-effects or any serious adverse consequences.

Neuropathic pain is a chronic condition with high unmet medical need as approximately 40% of patients do not respond to current first-line treatment and a further 25% do not respond to second-line treatment options.

It is estimated that up to 8% of the adult population suffer from chronic pain with neuropathic characteristics.